ReviewNature reviews. Rheumatology2024
Platelets in Kawasaki disease: mediators of vascular inflammation.
Review in Nature reviews. Rheumatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Aspirin dose and coronary artery lesions in Kawasaki disease: a two-center retrospective comparative effectiveness study.European journal of pediatrics · 2026Article
- Inflammatory burden and coronary aneurysm risk in Kawasaki disease: appraising the Aggregate Index of Systemic Inflammation.Pediatric research · 2026Article
- Association of the Aggregate Index of Systemic Inflammation with coronary artery aneurysm in Kawasaki disease patients.Pediatric research · 2026Article
- Machine learning model for intravenous immunoglobulin resistance in Kawasaki disease: model development and validation study.World journal of pediatrics : WJP · 2026Article
- Predicting coronary artery lesions in Kawasaki disease: a nomogram based on LASSO regression feature selection.BMC medical informatics and decision making · 2026Article
- The expression of C-reactive protein, erythrocyte sedimentation rate, and procalcitonin in children with Kawasaki disease and their correlation with coronary artery ectasia.BMC pediatrics · 2026Article
- Advance in the Kawasaki disease related coronary artery aneurysms: knowledge mapping, trends, and research frontiers.Journal of cardiothoracic surgery · 2026Review
- Neutrophil reprogramming underlie vasculopathy and lung disease in systemic sclerosis.Cell death & disease · 2026Article
- [cGAS-STING signaling pathway in Kawasaki disease: mechanistic insights and advances in clinical applications].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2026Review
- Phillyrin alleviates Kawasaki disease-induced lung inflammation by inhibiting platelet production through the NLRP3/IL-1β/NF-E2 signaling pathway.Chinese medicine · 2026Article
- Resveratrol ameliorates myocardial injury and inflammatory response and cell apoptosis in Kawasaki disease rats by activating the Nrf2/HO-1 pathway.Journal of cardiothoracic surgery · 2026Article
- Thrombo-inflammation and Rethinking the Role of Aspirin in Kawasaki Disease.Current rheumatology reports · 2026Review
- Clinical correlation between platelet parameters and coronary artery lesions in pediatric Kawasaki disease.Frontiers in pediatrics · 2026Article
- Kawasaki disease shock syndrome with pulmonary involvement in a child: a case report.Frontiers in immunology · 2026Article
- Impact of breastfeeding andFrontiers in immunology · 2026Article
- Elevated platelet-to-lymphocyte ratio is associated with stroke-associated pneumonia in acute ischemic stroke: a retrospective cohort study.Frontiers in neurology · 2026Article
- Development and internal validation of a monocyte-to-albumin ratio-based risk assessment model for coronary artery lesions in Kawasaki disease.Frontiers in pediatrics · 2026Article
- Stratified assessment of platelets in sepsis: from dynamic counts to functional phenotypes.Frontiers in immunology · 2026Review
- Single-cell multi-omics sequencing reveals the immunological disturbance underlying Kawasaki disease.Frontiers in molecular biosciences · 2026Article
- A nomogram for predicting the risk of persistent coronary artery aneurysms in children with Kawasaki disease: a retrospective study.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kawasaki disease, a systemic vasculitis that affects young children and can result in coronary artery aneurysms, is the leading cause of acquired heart disease among children. A hallmark of Kawasaki disease is increased blood platelet counts and platelet activation, which is associated with an increased risk of developing resistance to intravenous immunoglobulin and coronary artery aneurysms. Platelets and their releasate, including granules, microparticles, microRNAs and transcription factors, can influence innate immunity, enhance inflammation and contribute to vascular remodelling. Growing evidence indicates that platelets also interact with immune and non-immune cells to regulate inflammation. Platelets boost NLRP3 inflammasome activation and IL-1β production by human immune cells by releasing soluble mediators. Activated platelets form aggregates with leukocytes, such as monocytes and neutrophils, enhancing numerous functions of these cells and promoting thrombosis and inflammation. Leukocyte-platelet aggregates are increased in children with Kawasaki disease during the acute phase of the disease and can be used as biomarkers for disease severity. Here we review the role of platelets in Kawasaki disease and discuss progress in understanding the immune-effector role of platelets in amplifying inflammation related to Kawasaki disease vasculitis and therapeutic strategies targeting platelets or platelet-derived molecules.
Indexed as
Identifiers
38886559What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.